Findings About the Effectiveness of Total-Body Skin Cancer Exams and Concerns About Cancer Management Delayed by COVID-19 Earn Advanced Dermatology Researchers National Attention

MAITLAND, Fla., Feb. 16, 2021 /PRNewswire/ -- Concerns over the magnitude of COVID-19's effect on the timely detection and management of melanoma and non-melanoma skin cancers has led an elite team of researchers, including Dr. James Solomon and Dr. Matt Leavitt of Advanced Dermatology and Cosmetic Surgery, to participate in research that has been published in the January 19, 2021 edition of the Journal of the American Academy of Dermatology (JAAD).

Dr. Solomon and Dr. Murray Cotter also participated in a recent study that demonstrated the effectiveness of total-body skin cancer exams, which was published in the Journal of Clinical Oncology®, an American Society of Clinical Oncology (ASCO) Journal.

"Reduced access to care due to COVID-19 has raised concerns that patients with potential skin cancers may have had material delays in detection and care," said Dr. Solomon, who is the Director of Research and Principal Investigator of Ameriderm Research, the research division of Advanced Dermatology. "This study assessed the magnitude of delays in initial skin cancer diagnosis and management."

With institutional review board approval, data from January 2019 to August 2020 were analyzed from available outpatient-chart reviews of 143 US dermatology practices (350 providers) covering 4.7 million patients across 13 geographically distributed states. The number of diagnosed cutaneous melanomas, cutaneous squamous cell carcinomas (SCCs), and basal cell carcinomas (BCCs) was determined.

"Total 2020 skin cancer diagnoses trailed that of 2019, with 279 fewer cutaneous melanomas, 6000 fewer cutaneous SCCs, and 9914 fewer BCCs detected," said Dr. Solomon.

"Extrapolating these findings to the full US population (330 million), an estimated 19,600 cutaneous melanomas, 421,300 cutaneous SCCs, and 696,100 BCCs have had materially delayed initial diagnosis or treatment."

"Although skin cancer diagnoses have now returned to the same-month 2019 baseline, our findings suggest that a large backlog of skin cancers remains undiagnosed. These delays may lead to skin cancers presenting at more advanced stages."

The ASCO published study explored the effectiveness of dermatology providers performing total-body skin cancer exams versus partial skin exam screenings and concluded that skin cancer is detected at significantly higher rates using total-body skin cancer exams. In fact, it concluded a total-body skin cancer exam is 23.5 times more likely to identify a melanoma than a Pap smear is to identify a cervical cancer.

"The bottom line is that skin cancer didn't take a break due to COVID-19," said Dr. Solomon. "If you're due for your annual total-body skin cancer exam, get it on your calendar. We're taking strict safety measures to protect your health and to give you the peace of mind to get the care you need."

ABOUT AMERIDERM RESEARCH

Ameriderm Research was created in 2006 by Advanced Dermatology and Cosmetic Surgery Executive Chairman and Founder Dr. Matt Leavitt, to find new and better ways to treat patients with dermatologic conditions through FDA-supervised clinical trials of leading-edge drugs, devices and other treatments. Ameriderm Research's Director of Research and Principal Investigator James A. Solomon, MD, PhD, has been performing clinical trials since the 1970s and has assembled a highly skilled team which conducts its clinical trials in Ormond Beach, FL. To learn more about Ameriderm Research or to inquire about our clinical trials, visit www.AmeridermResearch.com. 

ABOUT ADVANCED DERMATOLOGY AND COSMETIC SURGERY

With more than 140 offices in 14 states, Advanced Dermatology and Cosmetic Surgery is the nation's premier dermatology practice. Advanced Dermatology is committed to providing comprehensive and unparalleled dermatologic and aesthetic care in a welcoming and engaging environment and seeks to combine the best of the art of medicine with the latest advances in research and technology. To learn more, visit AdvancedDerm.com.

Contact

Sheryl Garelick 
PRfect Creative

Cell: 352.255.9731 |
[email protected]

SOURCE Advanced Dermatology and Cosmetic Surgery